Nyrada Inc
ASX:NYR

Watchlist Manager
Nyrada Inc Logo
Nyrada Inc
ASX:NYR
Watchlist
Price: 0.75 AUD 2.04% Market Closed
Market Cap: 158.2m AUD

Relative Value

The Relative Value of one NYR stock under the Base Case scenario is 0.07 AUD. Compared to the current market price of 0.75 AUD, Nyrada Inc is Overvalued by 91%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NYR Relative Value
Base Case
0.07 AUD
Overvaluation 91%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
1
vs Industry
12
Median 3Y
6.8
Median 5Y
12.9
Industry
2.6
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-5.9
Industry
21.7
vs History
vs Industry
Median 3Y
-7.1
Median 5Y
-8.3
Industry
16.7
vs History
vs Industry
Median 3Y
-7
Median 5Y
-8.3
Industry
23.1
vs History
1
vs Industry
20
Median 3Y
2.5
Median 5Y
2.7
Industry
2.2
vs History
1
vs Industry
15
Median 3Y
4.2
Median 5Y
8.6
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
55
Median 3Y
-3.1
Median 5Y
-3.8
Industry
13.2
vs History
vs Industry
52
Median 3Y
-3.1
Median 5Y
-3.8
Industry
16.8
vs History
vs Industry
54
Median 3Y
-3.9
Median 5Y
-4.7
Industry
15.9
vs History
vs Industry
42
Median 3Y
-3.9
Median 5Y
-4.7
Industry
19.2
vs History
1
vs Industry
2
Median 3Y
31.8
Median 5Y
18.6
Industry
1.9

Multiples Across Competitors

NYR Competitors Multiples
Nyrada Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Nyrada Inc
ASX:NYR
158.2m AUD 61.8 -32.6 -32 -32
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55 36.9 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
496.6B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
259.2B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.2 108.4 158.6
CH
Novartis AG
SIX:NOVN
208.2B CHF 4.7 18.2 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
251.4B USD 3.9 13.2 9.4 11.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
AU
Nyrada Inc
ASX:NYR
Average P/E: 24
Negative Multiple: -32.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
18.2
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Nyrada Inc
ASX:NYR
Average EV/EBITDA: 438.8
Negative Multiple: -32
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Nyrada Inc
ASX:NYR
Average EV/EBIT: 1 881.3
Negative Multiple: -32
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
14.9
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.2
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3